Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health

TAGS

Lupin Limited said that , its 100% subsidiary in Brazil, has agreed to acquire all rights to nine drugs from Companies’ subsidiary BL Indústria Ótica.

The financial terms of the deal were not disclosed.

Through the deal, MedQuímica will gain rights to the three drugs — Limbitrol, Melleril, and Dalmadorm, five topical oncological treatments — Bacrocin, Solaquin, Glyquin, Efurix, and Oxipelle, and drug Cuprimine.

See also  Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn

Alexandre Franca — MedQuímica Managing Director said: “The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness.

“This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This